Richard Moriggl participated in the first Dotan International Symposium at Tel Aviv University.
The ultimate goal of translational cancer research is to harness biology for the cure of hematological malignancies.
Such research was the focus of the first international Dotan Symposium and an international panel of eminent scientists discussed recent progress in the field. Two diffrent approaches for targeting hematological malignancies were reviewed by the participants: targeting specific genes and pathways within the malignant cells and targeting the cancer phenotype, mainly by manipulating the immune system. The future therapy of hematological cancers is likely to benefit from combining these promising approaches.